行情

AXSM

AXSM

Axsome
NASDAQ

实时行情|Nasdaq Last Sale

54.99
-0.80
-1.43%
交易中 15:30 04/02 EDT
开盘
54.99
昨收
55.79
最高
56.56
最低
53.77
成交量
70.59万
成交额
--
52周最高
109.94
52周最低
13.11
市值
20.39亿
市盈率(TTM)
-27.5211
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测AXSM价格均价为152.00,最高价位220.00,最低价为100.00。

EPS

AXSM 新闻

更多
  • 瑞幸爆出财务造假丑闻 股价一度狂跌八成
  • 新浪美股 · 40分钟前
  • 特朗普称沙特和俄罗斯同意减产约1000万桶 但消息未获沙特证实
  • 新浪美股 · 1小时前
  • 特朗普宣称石油减产遭“打脸” 油价经历过山车行情
  • 新浪财经-自媒体综合 · 1小时前
  • 午后:油价大起大落 美股涨幅收窄
  • 新浪美股 · 1小时前

所属板块

生物技术和医学研究
+1.96%
制药与医学研究
+1.83%

热门股票

代码
价格
涨跌幅

AXSM 简况

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).
展开

微牛提供Axsome Therapeutics Inc(NASDAQ-AXSM)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的AXSM股票新闻,以帮助您做出投资决策。